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The B cell receptors (BCRs) for antigen express variable (V) regions
that are enormously diverse, thus serving as markers on individual
B cells. V region-derived idiotypic (Id) peptides can be displayed as
pId:MHCII complexes on B cells for recognition by CD4+ T cells. It is
not known if naive B cells spontaneously display pId:MHCII in vivo
or if BCR ligation is required for expression, thereby enabling col-
laboration between Id+ B cells and Id-specific T cells. Here, using a
mouse model, we show that naive B cells do not express readily
detectable levels of pId:MHCII. However, BCR ligation by Ag dra-
matically increases physical display of pId:MHCII, leading to acti-
vation of Id-specific CD4+ T cells, extrafollicular T–B cell collaboration
and some germinal center formation, and production of Id+ IgG.
Besides having implications for immune regulation, the results
may explain how persistent activation of self-reactive B cells induces
the development of autoimmune diseases and B cell lymphomas.
idiotype-driven T–B collaboration | M315-like BCR | idiotypic peptide:
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Each B cell expresses unique BCR variable (V) regions due toV(D)J recombination and somatic hypermutation (1). The
highly diversified V regions express idiotypic (Id) determinants
that can be recognized by antibodies (2) and by CD4+ T cells (3).
B lymphoma cells constitutively antigen-process their BCR
and present Id peptides on their MHC class II molecules
(pId:MHCII) to Id-specific CD4+ T cells (4, 5). Consistent with
this, Id peptides were eluted from MHC class II molecules of
tumor B cells (6). On the basis of these results, it was proposed in
1993 that Id-specific T cells help B cells that display pId:MHCII
complexes on their surface (7). Such Id-driven T–B collaboration
appears to be limited to rare Id peptides that express somatic
mutations or unique N-region sequences (3, 8–11), since T cells
are tolerized to germline-encoded V region sequences (8, 12).
The existence of Id-driven T–B collaboration has been supported
by studies using paired Ig/TCR-transgenic mice in 2 independent
models (7, 13, 14). Chronic Id-driven T–B collaboration in these
models has been associated with development of SLE-like au-
toimmune disease (13–16) and even B cell lymphomas (17).
The relevance of Id-driven T–B collaboration to disease de-
velopment has been supported by recent observations in humans.
First, bioinformatic analysis has indicated that human Ig V-regions
are enriched for sequences that bind MHC molecules (18). Sec-
ond, signs of Id-driven T–B collaboration have been observed in
multiple sclerosis patients (19–21). Third, evidence of Id-driven
T–B collaboration was obtained in chronic lymphatic leukemia
(CLL) patients (22). Fourth, Id peptides were readily isolated
from MHC class II molecules of mantle cell B lymphomas (23),
as well as follicular B cell lymphomas, diffuse large B cell lym-
phoma, and CLL (24).
As an explanation for the pathogenicity of Id-driven T–B col-
laboration, it has been hypothesized that autoreactive B cells, in
lieu of help from self antigen-specific T cells (that are tolerized),
could instead receive help from Id-specific CD4+ T cells (13, 25).
It was further hypothesized that BCR ligation by self antigen could
contribute to such pathogenic Id-driven T–B collaboration (13,
25). In support of the hypothesis, BCR ligation caused a GC re-
action and isotype switch; however, the experiments employed
memory B cells and Th2 cells, not naive cells (13).
To investigate the unresolved issue of whether BCR ligation is
required for Id-dependent collaboration between naive B and
T cells in vivo, we have here generated a strain of mice that have
a low frequency of B cells with a BCR that (i) can be deliberately
ligated by antigen and (ii) contains a particular Id sequence in its
V region. The model employs a type of V gene segment-modified
mice that yields physiological expression of the Id sequence only
subsequent to a Vλ2 → Jλ2 rearrangement in developing B cells.
The surface display of pId:MHCII was physically detected by a
staining reagent. The results show that naive B cells do not express
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detectable levels of pId:MHCII. However, BCR ligation induces
pId:MHCII display, thereby enabling Id-driven T–B collaboration.
The findings support a mechanism where BCR ligation by self
antigen is required for display of pId:MHCII on autoreactive B
cells and solicitation of help from Id-specific T cells.
Results
A Model System for Studying the Influence of BCR Ligation on Id-
Driven T–B Collaboration. The M315 myeloma protein produced
by the MOPC315 myeloma cell line binds defined ligands such as
anti-Id mAbs (26) and DNP/TNP haptens (27) (Fig. 1A). Its L
chain (λ2315) contains a mutated Id sequence that spans the V–J
junction in the CDR3 loop. Upon antigen processing by APCs, the
Id peptide is released and binds to the MHC class II molecule I-Ed
for presentation to Id-specific CD4+ T cells (3, 4) (Fig. 1A).
To study the role of BCR ligation in Id-driven T–B collabo-
ration, we developed two strains of mice that express the VH and
the VL of M315, respectively. Upon cross-breeding, the offspring
should express an M315-like BCR on a low proportion of their B
cells. For the VH, we made a conventional BCR knock-in mouse
where a rearranged and moderately mutated VDJH
315 was placed
in the JH locus (SI Appendix, Figs. S1 and S2 A and B). For the VL,
we generated a type of V gene segment-modified mouse where
nine nucleotides encoding the amino terminal part of the mutated
Id peptide replaced the corresponding germline nucleotides in the
Vλ2 gene segment (Fig. 1B and SI Appendix, Fig. S3 A and B). In
rare B cells, where the modified Vλ2315m rearranges to the Jλ2, a
recombined VJ is generated that should encode the entire mu-
tated Id315 peptide. The F1 progeny of these two strains, called
Id315 mice, should express an M315-like BCR on a small subset of
their B cells. Such rare Id+ B cells were tested for collaboration
with Id-specific CD4+ T cells from previously described TCR-
transgenic mice (28), either in the presence or the absence of
BCR ligation by defined ligands (Fig. 1C).
Characterization of Gene-Modified Strains of Mice. In the VDJH
315
mouse, allelic exclusion was pronounced, and VDJH
315 was expressed
by most B cells (SI Appendix, Fig. S2 C–H). B cell development in
the bone marrow was slightly accelerated (SI Appendix, Fig. S3G),
as is commonly found in VDJ knock-in mice. In the Vλ2315m
mouse, codons 94, 95, and 96 of the germline Vλ2 were exchanged
with those of Vλ2315expressed by MOPC315. Since the FRT re-
combination left a short residual sequence within the intron im-
mediately downstream of Vλ2315m (SI Appendix, Fig. S3A), the
Fig. 1. A model system for studying the influence of BCR ligation on idiotype-driven T–B collaboration. (A) The M315 monoclonal Ig binds the indicated
ligands. The λ2315 L chain expresses a mutated CDR3 Id peptide (residues 92 to 100; red triangle) that, after antigen processing, is presented on the MHC class II
molecule I-Ed. (B) In Vλ2315m mice, the germline Vλ2 gene segment was modified by the exchange of 9 nucleotides so that the modified Vλ2 allele encodes the
mutated residues F94R95N96 of the central part of the Id sequence. (C) Offspring from a Vλ2315m × VDJH315 cross, called Id315 mice (Left), should have a low
frequency of B cells with an Id+ M315-like BCR that can be deliberately ligated. Id-driven T–B collaboration (Center) can be tested using Id-specific CD4+ T cells
from previously established TCR-transgenic mice (Right). (D) The prevalence of germ line (YST) and mutated (FRN) sequences in λ2 encoding mRNAs in splenic
CD19+ B cells of heterozygous Vλ2315m mice. (E) Map of the Vλ2315m → Jλ2 junction containing the mutated FRN sequence (pink letters) within the minimal Id
peptide. The prevalence of various amino acids at the junctional position 98 is indicated. (F) In vitro response (BrdU incorporation) of Id-specific T cells to
synthetic peptides with varying junctional residues presented by splenic APCs. (G) Frequency of Id315 BCR+ B cells in the circulation of Id315 and BALB/c mice
detected using biotinylated DNP-albumin and λ2/3 L chain-specific (2B6 mAb) staining (n = 5 per group). (H) Frequency of Id315 BCR+ B cells detected using
anti-Id mAb (Ab2-1.4) that requires association of VDJH
315 and Vλ2315m chains for its binding (n = 10 Id315; n = 4 BALB/c). (I and J) DNP-specific (I) or Ab2-1.4-
specific (J) antibodies in the sera of Id315 and BALB/c mice (n = 6 to 9 per group). Statistical comparisons: unpaired t tests (G–J). **P ≤ 0.01, ***P ≤ 0.005.



























































recombination frequency to Jλ2 could have been influenced. To
test this, we analyzed the frequencies of Vλ2 → Jλ2 rearrange-
ments on the WT and Vλ2315m chromosomes in heterozygous
Vλ2315m mice by cDNA amplicon sequencing (29). Both tran-
scripts were expressed, although Vλ2315m–Jλ2 joints were found
at a slightly lower frequency than Vλ2–Jλ2 joints (Fig. 1D). At
the Vλ2–Jλ2 junction, residue 98 varies due to junctional di-
versity (30). We found that the rearranged WT and Vλ2315m
alleles had an identical frequency of different amino acids in
position 98 with the ranking order Tyr>>Phe∼Leu (Fig. 1E).
Since the minimal Id peptide (residues 92 to 100) spans the VJ
junction, we tested synthetic peptides with naturally occurring
amino acids at position 98 for their ability to stimulate Id-specific
CD4+ T cells. Peptides with both Tyr98 and Phe98 residues were
fully compatible with stimulation of Id-specific CD4+ T cells,
while Leu98 was not (Fig. 1F). This result indicates that most B
cells in which a Vλ2315m → Jλ2 rearrangement occurs should
potentially be able to stimulate Id-specific T cells. The frequencies
and specific lineages of λ2/3+ B cells (detected by a Cλ2/Cλ3 cross-
reactive mAb, 2B6) and the levels of total λ2/3+ serum Ig did not
differ between Vλ2315m and BALB/c mice (SI Appendix, Fig. S3
D–G). These results indicate that the V gene segment modifica-
tion in Vλ2315m did not influence B cell development, so the
mouse strain displayed a physiological B cell compartment.
Offspring of homozygous VDJH
315 and Vλ2315m mice, called
Id315 mice, had a slightly accelerated development of B cells in the
bone marrow and a small increase in λ2/λ3+ T2 cells in the spleen,
but were otherwise normal (SI Appendix, Fig. S3 F and G). These
changes are most likely due to the prearranged VDJH
315 compo-
nent of Id315 mice (SI Appendix, Fig. S2A). In Id315 mice, ∼3 to 4%
of circulating B cells expressed an M315-like BCR detected by
binding of DNP (Fig. 1G), while ∼1.5% were detected by the anti-
Id IgG1 Ab2-1.4 (26) (Fig. 1H), consistent with the fine specificity
differences between these two BCR ligands (SI Appendix, Table
S1) (26) (also detailed later). The result with the highly specific
Ab2-1.4 mAb (Fig. 1H) is as expected, since Vλ2315m → Jλ2
rearrangements should only occur in ∼1 to 2% of peripheral B
cells (30). Id315 mice had about ∼1 to 2 μg/mL of serum IgG that
bound DNP (Fig. 1I) and ∼0.3 to 0.8 μg/mL that bound anti-Id
Ab2-1.4 mAb (Fig. 1J), again consistent with the fine specificity of
these reagents (SI Appendix, Table S1) (26). Collectively, these
results indicate that VDJH
315, Vλ2315m, and Id315 mice displayed
the expected features.
Id315 mice were used in most of the in vivo experiments de-
scribed herein. However, in some experiments (e.g., adoptive
transfers to CD45.1+ congenic BALB/c mice), large numbers of
Id315 B cells (hereafter called Id+ B cells) were needed. For this
purpose, VDJH
315 mice were crossed with previously described λ2315
transgenic mice (31). In the progeny, as much as 70 to 80% of
peripheral B cells expressed an M315 BCR (SI Appendix, Fig. S4
A and B). In λ2315TG × VDJH315 mice, splenic B cells had
slightly reduced IgM expression levels (SI Appendix, Fig. S4C),
and marginal zone (MZ) B cells were increased relative to follicular
(FO) B cells (SI Appendix, Fig. S4D). Nevertheless, Id+ B cells from
the progeny were fully responsive to stimulation. Pre-B and pro-B
cells in the bone marrow were reduced, but mature B cells were
found to be at normal levels (SI Appendix, Fig. S4E). Since acti-
vated B and T cells may modulate their surface antigenic recep-
tors, the use of CD45.1+ congenic mice facilitated the detection of
the transferred lymphocyte populations upon recovery.
Characterization of Specificity of BCR Ligands. The amino acid ex-
changes introduced in positions 94, 95, and 96 of Vλ2315m, as well
as the junctional variation in position 98 in Vλ2315m-Jλ2 joints
(Fig. 1E), could influence the binding of anti-Id mAb Ab2-
1.4 and DNP/TNP used as ligands for the Id+ BCR (Fig. 1A).
To investigate this, we established a panel of recombinant IgGs
that express VH
315 together with various Vλ2-regions and tested
these for binding to the anti-idiotypic mAb Ab2-1.4 as well as
DNP and TNP haptens (SI Appendix, Table S1). In brief, the Ab2-
1.4 bound VH
315 associated with Vλ2315m but not with germline
Vλ2. Moreover, Ab2-1.4 binding was compatible with the
three most frequent amino acids found in position 98: Tyr, Phe,
and Leu (Fig. 1E). The germline equivalent of VH
315, VH3-
6*02, was also compatible with binding, while a quite different
VH, VH
A20, was not. However, VH3-6*02 is probably poorly
expressed in Id+ mice due to the prerearranged VDJH
315. In
conclusion, Ab2.1.4 is a highly specific ligand for the BCR of Id+ B
cells and should bind all BCRs independent of junctional varia-
tion. Its affinity for Id+ M315 is KA = 7.7 × 10
6 M−1 (32).
TNP and DNP BCR ligands have a broader specificity since
either of the haptens bound to VH
315 and VH3-6*02 (but not
VH
A20) associated with either Vλ2315m or Vλ2 (SI Appendix,
Table S1). Junctional variation in position 98 did not influence
binding. These results extend a previous study demonstrating that
TNP and DNP bind VH
315 associated with either λ1, λ2, and
λ3 light chains, but not κ light chains (26). Thus, TNP/DNP should
bind BCRs that express endogenous λ-chains together with VH315
in Id315 mice. The affinity of DNP for M315 has been measured to
be in the range of KA= 1.6 × 10
5 to 3.9 × 106 M−1 (33), and the
affinities of DNP and TNP are in a similar range (34).
In the course of the experiments described later, TNP/DNP
and Ab2-1.4 were used not only as BCR ligands but also to mea-
sure B cell and antibody responses. Somatic hypermutation could
have influenced binding and detection, which is difficult to control
for. However, this does not seem to have been a major issue, since
potent responses were detected by the BCR ligands over pro-
longed periods of time.
BCR Ligation Is Required for Id-Driven T–B Collaboration in Vitro. We
performed a series of in vitro experiments on naïve splenic Id+ B
cells enriched through immunomagnetic depletion. Exposure of
Id+ B cells to Ab2-1.4 (hereafter referred to as anti-Id IgG) as
BCR ligand resulted in intracellular Ca2+ mobilization (Fig. 2A),
protein phosphorylation (Fig. 2B), and up-regulation of MHC
class II (Fig. 2C) and CD86 (Fig. 2D), but not CD80, cell surface
expression. Similar, although slightly lower, responses were obtained
with DNP-OVA and TNP-OVA as BCR ligands (SI Appendix, Fig.
S5). Importantly, BCR ligation resulted in an increased display of
Id peptide–MHC class II complexes on the B cell surface, de-
tected by an scFv reagent specific for the pId315:I-Ed complex
[hereafter called pId:I-Ed or pId:MHCII; the reagent detecting
this complex is hereafter called a TCR mimetic (TCRm); Fig. 2E;
see also SI Appendix, Fig. S6]. Expression of pId:I-Ed was first
detected after 18 to 20 h and remained elevated for at least 45 h
after ligation (Fig. 2F and SI Appendix, Fig. S6G). When naïve Id+
B cells were mixed with naïve Id-specific T cells, BCR ligation
induced T cell–B cell conjugate formation within 30 min (Fig. 2G).
In cocultures of Id+ B cells and Id-specific T cells, ligation of the
Id+ BCR by anti-Id IgG resulted in the proliferation of B cells and
T cells (Fig. 2 H and I). These in vitro results show that BCR li-
gation enhances Id-driven T–B collaboration and that up-
regulation of pId:MHCII is a likely contributor.
It was of interest to assess whether pId:MHCII expression
increased only as a consequence of a general up-regulation of
MHC class II molecules, and whether BCR ligation was required.
To investigate this possibility, Id+ B cells were BCR-ligated with
TNP-OVA and compared with stimulation by the TLR4 ligand
LPS (SI Appendix, Fig. S7). LPS stimulation increased the MFI
signal of MHCII expression more than 5-fold, whereas pId:MHCII
expression was essentially unaltered. The inverse was observed
with TNP-OVA as BCR ligand. These results argue that BCR
ligation resulted in a specific up-regulation of pId presentation on
MHC class II molecules.







































BCR Ligation Is Required for Id-Driven T–B Collaboration In Vivo. We
first tested the effect of BCR ligation on Id+ B cells in vivo in the
absence of Id-specific T cells. A cohort of Id315 mice were injected
i.v. with anti-Id IgG or isotype-matched specificity control mAb,
and splenic Id+ B cells were analyzed by FACS at the indicated
time points. Within 24 to 48 h, BCR ligation enhanced the surface
expression of MHC class II molecules, CD86, and pId:MHCII
complexes on Id+ B cells (Fig. 2 J–L and SI Appendix, Fig. S6F).
The increased expression was still detectable after 72 h. These
results suggest that in vivo provision of BCR ligand prepares Id+ B
cells for efficient interaction with Id-specific T cells through sur-
face display of both pId:MHCII and costimulatory molecules. Up-
regulation of pId:MHCII was observed already at 24 h (Fig. 2L),
while a general up-regulation of MHCII was seen first after 48 h
(Fig. 2J), again arguing that BCR ligation has a specific con-
tribution to increased display of pId:MHCII.
To probe the sensitivity of the model for Id-driven T–B col-
laboration, we titrated the amounts of Id-specific T cells, anti-Id
IgG, and Id+ B cells needed to obtain Id+ IgG responses in Id315
and in CD45.1 congenic BALB/c recipients. Transfer of 15,000
naive T cells and 4 μg anti-Id IgG sufficed to elicit full Id+ Ig
responses in Id315 recipients (SI Appendix, Fig. S8 A and B). Even
as little as 1,500 Id-specific T cells induced Id+ IgG levels above
background levels. Assuming a 10 to 15% parking efficiency, this
cell dose is estimated to result in a physiological frequency of the
Id-specific T cells in the recipient (35). Naive Id+ B cells were
titrated by transfer into CD45.1+ congenic BALB/c mice together
with saturating dose of naive Id-specific T cells and anti-Id IgG.
About 105 Id+ B cells were required to elicit Id+ IgG responses (SI
Appendix, Fig. S8C).
Based on these results, we transferred naïve Id-specific T cells
and Id+ B cells, enriched through immunomagnetic depletion of
nondesired populations, into CD45.1+ congenic BALB/c mice,
followed by anti-Id IgG or isotype-matched control IgG and a
continuous BrdU administration (Fig. 3A). A number of conclu-
sions could be made based upon analysis of recipient spleens (Fig.
3) and lymph nodes (SI Appendix, Fig. S9). In the spleen, BCR
ligation increased the numbers of (i) donor-derived CD45.2+ cells
(Fig. 3B), (ii) Id-specific CD4+ T cells that had incorporated BrdU
(Fig. 3 C and D), (iii) follicular T helper cells (TFH; Fig. 3E), (iv)
Id+ B cells that had incorporated BrdU (Fig. 3F), and (v) germinal
center (GC) B cells (Fig. 3G). Intracellular staining of recovered
Id-specific T cells revealed that BCR ligation increased expression
of IFN-γ, TNF-α, and IL-4 cytokines and the transcription factor
T-Bet (Fig. 3H), whereas GATA-3 and Foxp3 were not detected.
Responses were stronger in the spleen than in the lymph nodes (SI
Appendix, Fig. S9). BCR ligation induced a 3- to 4-log10 increase in
serum levels of Id+ IgG of all subclasses (Fig. 3I).
Some of the anti-Id mAb Ab2-1.4 (IgG1) used in the afore-
mentioned experiments could have been internalized via FcγRIIb
on B cells rather than through receptor-mediated uptake, which
could have contributed to pId:MHCII presentation. To exclude
this possibility, we generated F(ab)2 fragments of the anti-Id IgG
(SI Appendix, Fig. S10). F(ab)2 fragments were at least as stimu-
latory as intact anti-Id mAb to initiate Id-driven T–B cell collab-
oration, demonstrating that the Fc region and uptake via FcγRIIb
is dispensable for responsiveness to BCR ligation (SI Appendix,
Fig. S11).
In these experiments, the necessity of BCR ligation for initiation
of Id-driven T–B collaboration was demonstrated with naive B and
T cells. However, it has been previously demonstrated that naive B
cells, although unable to stimulate naive T cells, can stimulate
memory T cells (36). Consistent with this, it was shown that naive
B cells from λ2315-transgenic mice could stimulate Id-specific Th2
cells in the absence of BCR ligation (37). We therefore tested if
naive Id+ B cells in Id315 mice could collaborate with in vitro-
polarized Id-specific Th2 cells after adoptive transfer. The results
show that naive Id+ B cells can collaborate with Th2 cells in vivo;
however, addition of BCR ligation clearly enhanced responses (SI
Appendix, Fig. S12).
Localization of Id-Driven T–B Collaboration. To study the histologi-
cal correlates of BCR ligation, we transferred naïve Id-specific
T cells into Id315 mice, injected anti-Id IgG or isotype-matched
Fig. 2. Ligation of the Id+ BCR by antigen induces downstream signaling, Id peptide presentation on MHC-II, and stimulation of Id-specific T cells. (A–I) In vitro
experiments. Id+ B cells (enriched from λ2315TG × VDJH315 mice by negative selection) were stimulated with anti-Id IgG or added isotype-matched control IgG (10
μg/mL unless otherwise indicated). (A) Ca2+ flux assay. (B) Phosphotyrosine blots of cell lysates. (C–E) MHC-II (I-Ad/I-Ed), CD86, and pId315:I-Ed expression after 18 to
21 h in culture. The data represent fold increases in the geometric mean of FI signal of Id+ B cells added either anti-Id IgG or isotype control IgG. MFIG values from
nonstimulated Id+ B cells in each experiment were taken as a baseline. Fold up-regulation values were pooled from 2 to 3 individual in vitro assays. (F, Left)
Histogram plot of pId315:I-Ed expression on Id+ B cells measured after 48 h using the TCR mimetic scFv reagent. (F, Right) pId315:I-Ed presentation on Id+ B cells after
21 and 45 h. (G) Conjugate formation between Id+ B cells and Id-sp. T cells labeled with CFSE and CTV. (H and I) BrdU incorporation into Id+ B cells and Id-specific
T cells, measured during the last 14 h of a 4-d coculture. (J–L) In vivo experiments. Id315 mice were injected i.v. with 60 μg BCR ligand anti-Id IgG or isotype control
IgG, and splenic Id+ B cells were analyzed for expression of MHC-II (J), CD86 (K), and pId315:I-Ed (L; FACS plots shown in SI Appendix, Fig. S6F). Statistical com-
parisons: unpaired t tests (C–E, H, and I), Mann–Whitney U tests for BCR ligation versus control at each time point (F), and Dunnett’s multiple comparisons test for
baseline levels versus the different time points (J–L). *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.005, and ****P ≤ 0.001.



























































control IgG the next day, and analyzed spleens at different time
points after ligation (Fig. 4 and SI Appendix, Figs. S13 and S14).
Staining of sections for the GL7 lymphocyte activation marker
showed that BCR ligation induced a robust extrafollicular acti-
vation of B and T cells on day 3 and day 6; however, activation
had considerably subsided by day 9. Germinal centers (GCs) also
peaked early (day 3), but these still remained on day 9, although
they were fewer (SI Appendix, Fig. S13A and Fig. 4D; further
detail provided later). By immunofluorescence analysis using
mAbs specific for the Id+ BCR, the Id-specific TCR, the follicular
dendritic cell light zone marker CD35, and GL7, we found con-
siderable numbers of Id+ B cells and Id-specific T cells localized in
regions surrounding GL7+/CD35+ GCs. Moreover, direct contacts
(synapses) were observed between Id+ B cells and Id-specific T
cells outside GCs (Fig. 4B and SI Appendix, Fig. S14A). GL7+ GC
B cells stained only weakly with Ab2-1.4 anti-Id mAb (SI Appen-
dix, Fig. S14B, Top), most likely due to BCR down-regulation.
In contrast, stronger staining for the Id+ Ig, sometimes suggestive
of cytosolic accumulation, was detected in B cells outside the GC
(Fig. 4B and SI Appendix, Fig. S14A). In addition to their pre-
dominantly extrafollicular location, Id-specific T cells were also
observed, albeit more scarcely, in the GC (Fig. 4B and SI Appendix,
Fig. S14B). Staining for Ki-67 corroborated that proliferation oc-
curred both in GCs and in extrafollicular B cell clusters on day
3 postligation (SI Appendix, Fig. S14C).
Quantification revealed that BCR ligation increased specific
T–B synapses as well as GCs in spleen sections (Fig. 4 C and D).
Synapses as well as GCs were most frequent already on day 3,
and declined thereafter (Fig. 4 C and D). Synapses and GC for-
mation preceded the peak expansion of Id+ B cells (day 6; Fig. 4E)
and the peak of Id+ serum IgG (Fig. 4F). In summary, Id-driven
T–B collaboration appeared to occur predominantly in extra-
follicular sites and to a smaller extent in GCs. The latter appeared
small and of short duration, perhaps indicative of abortive GC
reactions. Analysis of stained sections (Fig. 4B and SI Appendix,
Figs. S13 and S14) revealed less robust GC responses than did the
FACS analysis (Fig. 3), where a preponderance of GC B cells and
TFH was found. Of note, for the FACS analyses, we used the
CD45.2 congenic marker, which is expressed irrespective of down-
modulation of the BCR or the TCR, thereby facilitating recovery
and enumeration of a larger proportion of the transferred cells.
Furthermore, the anatomical location of Id+ B cells could differ in
Id315 mice (natural positioning) compared to their location after
injection i.v. into CD45.1 congenic recipients, thereby influencing
the results.
Fig. 3. BCR ligation is required for idiotype-driven T–B collaboration in the spleen. (A) Experimental setup (Id-sp. T/anti-Id IgG, n = 6; Id-sp. T/isotype control
IgG, n = 4). (B–G) FACS analysis. The gated populations are shown: B cells, pink gates; T cells, blue gates. (B) Frequencies of donor lymphocytes (CD45.2+
CD45.1−). (C) Frequencies of Id-specific CD4+ T cells detected by the TCR clonotype-specific mAb GB113. (D) BrdU incorporation into Id-specific T cells. (E)
Follicular T helper cell differentiation of Id-specific T cells. (F) BrdU incorporation into Id+ B cells (CD45.2+ B220+). (G). Germinal center differentiation of Id+ B
cells. (H) Intracellular cytokine and intranuclear transcription factor expression by Id-specific CD4+ T cells. (I) Serum titers of Id+ (anti-Id Ig-reactive) IgG an-
tibody subclasses on day 11. Statistical comparisons: unpaired t tests (B–G), Mann–Whitney U tests (H and I). *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.005.







































Analysis of Id-Driven T–B Collaboration by Ig Gene Sequencing. On
day 7 of Id-driven T–B collaboration, using anti-Id F(ab)2 frag-
ments as BCR ligand (SI Appendix, Fig. S11), we purified PNA+
and PNA− B cells from Id315 mouse spleens and PCR-amplified
and sequenced light chain transcripts with primers specific for
λ1, λ2, and λ3 chains. The PNA+ fraction contained 20% GL7+
CD95+ cells by FACS, indicating ∼15 fold enrichment of GC B
cells. Sequence analysis showed that the PNA+ population was
almost completely dominated by Vλ2315m sequences having the
idiotypic FRN sequence in positions 94 to 96 (Fig. 4G). A similar
but less pronounced result was obtained for the PNA− pop-
ulation. These observations demonstrate a strong expansion of
Vλ2315m+ B cells, not only in the GC (PNA+) population, but
also in the non-GC (PNA−) population. The results support the
functional data (Figs. 3 and 4). Interestingly, the junctional
amino acid in Vλ2315m-Jλ2 sequences was exclusively F98 even
though Y98 was by far the most frequent junctional residue in
Vλ2315m-Jλ2 sequences of unstimulated B cells (Fig. 1E). The
level of nucleotide substitutions was surprisingly low, with most
sequences being unmutated or having only one mutation (Fig.
4H and SI Appendix, Fig. S15). The level of nucleotide substi-
tutions in Vλ2315m-Jλ2 transcripts was not significantly different
between the PNA+ population and the PNA− population (Fig.
4H). The paucity of mutations in the PNA+ cell population is
surprising and appears consistent with a limited GC response.
Ligation of the Id+ BCR Using a Hapten–Protein Conjugate Promotes
Id-Driven T–B Collaboration. M315 has a specificity for the struc-
turally similar haptens DNP and TNP (27), but does not bind the
NIP hapten. We therefore tested if BCR ligation by DNP- and
TNP-conjugated proteins could promote Id-driven T–B collab-
oration. CD45.1+ BALB/c mice were transferred with Id+ B cells
and Id-specific T cells, followed by TNP-OVA or NIP-OVA (spec-
ificity control). Thereafter, mice continuously received BrdU (Fig.
5A). High doses of hapten–OVA conjugates were used (200 μg),
since preliminary experiments suggested that DNP-OVA is rela-
tively inefficient at promoting Id-driven T–B collaboration in vivo
compared to anti-Id IgG (SI Appendix, Fig. S16). Several factors
could contribute to this difference. First, OVA is filtrated in the
kidneys (38), while the higher-MW anti-Id IgG is not. Second, B
cells expressing VDJH
315 together with other λ chains than λ2315m
could bind DNP/TNP conjugates (SI Appendix, Table S1) and thus
serve as a sink for DNP/TNP-OVA. Finally, the Ig structure of the
anti-Id IgG ligand could be particularly efficient at cross-linking
BCR due to matching distances between antigen binding sites of
Id+ and anti-Id Igs.
Despite the decreased sensitivity, BCR ligation by TNP-OVA
in vivo increased BrdU incorporation into both Id-specific T cells
and Id+ B cells compared to that seen with NIP-OVA (Fig. 5 B
and C). Further, BCR ligation increased the frequency of GC-
like Id+ B cells (Fig. 5D). Finally, BCR ligation enhanced the
serum levels of Id+ IgG of all subclasses (Fig. 5E). These results
show that BCR ligation with TNP-OVA enhances Id-driven T–B
collaboration.
BCR Ligation with a T Cell-Independent Type 2 Antigen Enhances Id-
Driven T–B Collaboration. In the experiments described here earlier,
endogenous T cell responses directed against the BCR ligand,
either anti-Id IgG or OVA, could have influenced the results. To
exclude this possibility, we tested DNP-FICOLL as a BCR ligand,
the rationale being that FICOLL is a polysaccharide that should
not be presented on MHC class II molecules to endogenous T
cells. Moreover, since DNP-FICOLL is a T cell-independent type
2 (TI-2) antigen, the experiment addresses whether Id-specific
CD4+ T cells influence B cell responses to a TI-2 antigen.
Id-specific T cells were transferred to Id315 mice followed by
DNP-FICOLL or NIP-FICOLL the next day (Fig. 6A). Responses
in the spleens were analyzed on day 10. Immunohistochemical
staining revealed an enhanced generation of GCs on day 10 when
using DNP-FICOLL compared to NIP-FICOLL (Fig. 6B), which
was verified by quantitative assessment (Fig. 6C). In the absence
of T cell help, BCR ligation by DNP-FICOLL elicited a slight
Fig. 4. Germinal centers form rapidly in Id315 mice upon ligation of the Id+
BCR. (A) Experimental setup (Id-sp. T/anti-Id IgG, n = 14; Id-sp. T/isotype
control IgG, n = 4). (B) Representative germinal center in the spleen of a
recipient mouse on day 3. Id-specific TCR (clonotype-specific mAb GB113,
red) and Id+ BCR (anti-Id BCR Ab2-1.4 mAb, blue) staining shows an area of
T cell–B cell interaction. Germinal center B cells were identified as GL7+
clusters (green) with the light zone indicated by the presence of follicular
dendritic cells (CD35, white). Examples of T–B synapses are magnified in 1
and 2. SI Appendix, Fig. S14B shows single stains contributing to the overlay.
(C) Quantification of specific T–B synapses based on transgenic receptor
expression in sections. Each data point represents the number of Id+ B/Id-sp.
T synapses counted in one ×20 field. (D) Quantification of germinal centers
from spleen cryosections (means per ×10 field). (E) Id+ B cells (Ab2-1.4-
reactive) among κ light chain negative splenic B cells by FACS analysis. (F)
Id+ IgG serum levels. (G) Frequencies of the different λ transcripts recovered
among PNA+ and PNA− fractions of sorted B cells. The B cells were sorted on
day 7 from spleens of Id315 mice primed with Id-specific T cells and anti-Id
F(ab)2 fragments (SI Appendix, Fig. S11). (H) Comparisons of mutational load
among Vλ2315m-Jλ2 L chain transcripts recovered from the PNA-positive and
PNA-negative fractions. Statistical comparisons: Dunnett’s multiple com-
parisons test (C and D), unpaired t tests (E, F, and H). *P ≤ 0.05, **P ≤ 0.01,
***P ≤ 0.005, and ****P ≤ 0.001; n.s., not significant.



























































expansion of Id+ (λ+) B cells, including GC B cells and plasma
cells, as determined by flow cytometry (Fig. 6 D and E and SI
Appendix, Fig. S17). Addition of Id-specific T cells enhanced the
expansion of Id+ B cells and promoted their differentiation into
GC B cells and plasma cells (Fig. 6 D and E and SI Appendix, Fig.
S17). Finally, the concentrations of serum IgM and IgG that
bound anti-Id mAb or DNP were enhanced in the presence of
DNP-FICOLL and Id-specific T cell help compared to control
groups (Fig. 6F). Taken together, the results show that a TI-2 BCR
ligand alone stimulates Id+ B cell responses weakly, but that pro-
vision of Id-specific T cell help significantly augments responses.
Further, recognition of the BCR ligand by endogenous polyclonal
T cells is not required for Id-driven T–B collaboration.
To test if the CD40L–CD40 axis was involved in Id-driven T–B
collaboration, we next tried to block responses to DNP-FICOLL
by repetitious injections of anti-CD40L mAb (Fig. 6G and SI
Appendix, Fig. S18). The results show that CD40L blockade in-
creased the levels of Id+ IgM while Id+ IgG of all subclasses were
decreased (Fig. 6G and SI Appendix, Fig. S18). Thus, CD40L is
involved in the IgM → IgG switch in the presence of Id+ B and
Id-specific T cells. Anti-CD40L mAb did not inhibit the IgM
response by Id+ B cells induced by DNP-FICOLL in the absence
of Id-specific T cells, consistent with DNP-FICOLL being a TI-2
antigen (SI Appendix, Fig. S19).
The experiment was extended to adoptive transfer of Id+ LPS
blasts and naïve Id-specific T cells to CD45-congenic recipients,
followed by injection of DNP-FICOLL (SI Appendix, Fig. S20A).
BCR ligation enhanced responses of Id+ LPS blasts, both in terms
of plasma cell differentiation and IgG production (SI Appendix,
Fig. S20 C–E). A slight expansion of Id-specific T cells was ob-
served in response to LPS blasts in the absence of ligation (SI
Appendix, Fig. S20B), but this did not result in IgG serum levels
above that observed in mice transferred LPS blasts only (SI Ap-
pendix, Fig. S20 D and E). These results indicate that nonspecific
activation of Id+ B cells through TLR4 is not sufficient to induce
collaboration with naïve Id-specific T cells, but that BCR ligation
is required. This may well relate to the importance of recognition
of pId:MHCII by Id-specific T cells, since the level of pId:MHCII
remained unchanged after LPS stimulation (SI Appendix, Fig. S7).
Ligation of the Id+ BCR Promotes the Development of Memory B
Cells, Bone Marrow Plasma Cells and Id-Specific Regulatory T Cells.
After having evaluated early responses to BCR ligation, we per-
formed experiments where responses were analyzed at later time
points, e.g., day 28 (SI Appendix, Fig. S21). Id+ B cells and Id-
specific T cells were transferred to CD45.1+ BALB/c mice
followed by specific BCR ligation (DNP-FICOLL) or nonspecific
control antigen (NIP-FICOLL). Four weeks later, the spleens and
bone marrow cells from femurs were analyzed (SI Appendix, Fig.
S21A). Id-specific regulatory T cells were found on day 28, and
had increased to ∼2% of recovered Id-specific T cells in the spleen
(SI Appendix, Fig. S21B). The development of Tregs required
BCR ligation. Formation of Id+ memory B cells (CD73+ CD273+)
in the presence of BCR ligation was also increased (SI Appendix,
Fig. S21C). Finally, bone marrow plasma cells were significantly
expanded in recipients that had received the BCR ligand (SI
Appendix, Fig. S21D), and serum antibodies specific for anti-Id
IgG and DNP were significantly elevated (SI Appendix, Fig. S21
E–H). Id+ plasma cells secreting Id+ IgM and Id+ IgG were also
found on day 40 in another experiment, where anti-Id IgG was
used as BCR ligand (SI Appendix, Fig. S22). These results show
that BCR ligation in Id-driven T–B collaboration has a long-
lasting influence.
Discussion
The present results demonstrate that BCR V region-derived Id
peptides are undetectable on MHC class II molecules of naïve B
cells, but that BCR ligation induces display. Further, in the pres-
ence of naive Id-specific CD4+ T cells, BCR ligation initiates the
full panoply of events of T cell–B cell collaboration, including T–B
synapse formation, mutual activation and proliferation, GC for-
mation with generation of GC B cells and TFH, extrafollicular T–B
cell responses, and an increase in plasma cells and antibody pro-
duction. Despite the expansion of Id+ B cells, the level of muta-
tions in their BCR L chain V region was surprisingly small.
Whether BCR-ligated Id-driven T–B cell collaboration requires
dendritic cells has not been addressed in the current work, although
DCs were dispensable during conventional T–B collaboration using
anti-Id BCR knock-in mice and Id+ M315 as antigen (39).
These results seemingly contradict previous functional studies
in mice (4, 5, 37) andMHCII elution studies in mice (6) and humans
(23, 24, 40), which have demonstrated spontaneous pId:MHCII
presentation without deliberate BCR ligation. However, these pre-
vious studies employed malignant B cells of unknown specific-
ity cultured in vitro, and a number of uncontrolled factors could
have contributed to constitutive pId:MHCII display. In more
Fig. 5. Ligation of the Id+ BCR by TNP-OVA enables Id-driven T–B collabo-
ration. (A) Experimental setup (n = 5 Id+ B/Id-sp. T/TNP-OVA; n = 4 Id+ B/Id-sp.
T/NIP-OVA). (B–D) FACS analysis. The gated populations are shown; B cells, pink
gates; T cells, blue gates. (B) BrdU+ Id-specific T cells among transferred T cells.
(C) BrdU+ donor B cells. (D) Id+ GC (CD38lo/-) B cells. (E) Serum titers of Id+ IgG
antibody subclasses on day 7. Statistical comparisons: unpaired t tests (B–D),
Mann–Whitney U test (E). *P ≤ 0.05, **P ≤ 0.01.







































physiologically relevant experiments, naive B cells from λ2315 Ig
L-transgenic mice stimulated Id-specific Th2 cells, but not naive
Id-specific CD4+ T cells (37). In a second Ig L-chain transgenic
model, B cells had to be activated in order to stimulate Id-
specific T cell hybridomas in vitro (41). In these studies, the Ig
L chain transgenic B cells had a polyclonal H chain repertoire,
thus making it difficult to exclude a contribution of BCR ligation
by unknown antigens to pId:MHCII display. The present study
removes many of the ambiguities of these previous studies. First, a
V gene segment-modified mouse was created that had a low fre-
quency of B cells, which, subsequent to a Vλ2 → Jλ2 rearrange-
ment, had a physiological expression of a defined Id sequence in
the BCR L chain. Second, these Id+ B cells expressed a defined H
chain (from VDJH knock-in mice), and thus had a BCR of known
specificity, equivalent to that of myeloma protein M315. Third,
naive Id+ B cells and naive Id-specific T cells were employed.
Fourth, relatively low (but still unphysiological [35]) numbers of B
and T cells were used in the cell transfer experiments. Fifth,
three different BCR ligands, including a TI-2 ligand, were
employed, with similar results. Sixth, display of pId:MHCII was
physically measured by a staining reagent, in addition to
functional readouts.
The mechanism by which BCR ligation by antigen enhances
pId:MHCII expression is unknown, but is most likely due to en-
hanced endocytosis and processing of ligated BCR. Thus, we
propose that ligation not only induces endocytosis, processing, and
presentation of Ag (42) but also of the BCR itself. This makes
sense, since the BCR and Ag components of the BCR–Ag com-
plex should follow the same track in the endocytic pathway and
should therefore be exposed to the same proteolytic enzymes in
endosomes. The idea is consistent with antigen receptor-directed
antigen “handover” to class II MHC molecules with the addition
that BCR fragments are also generated and transferred (43, 44).
Cathepsins L and S have been described to be involved in pro-
teolytic fragmentation of Ag (45) and may also be involved in
processing of the BCR. Interesting in this respect, in silico analysis
indicated that Cathepsin B, L, and S sites are enriched within and
immediately upstream of CDR3 regions in intrathecal IgG from
multiple sclerosis patients (21).This observation suggests that
CDR3 peptides could be preferentially released by antigen pro-
cessing of the BCR in endosomes.
However, other possibilities for the cellular origin of the pId
component of the pId:MHCII complex cannot be excluded. It
has previously been described that nascent Ig L chains experi-
mentally retained in the ER/Golgi can be the source of pId
displayed on MHCII of transfected B lymphoma cells (5). Since
BCR ligation resulted in an up-regulated expression of MHCII,
this mechanism could possibly increase the display of pId derived
from ER/Golgi. Moreover, since BCR ligation enhanced levels
of costimulatory molecules, pId:MHCII complexes on B cells
could more potently elicit T cell responses.
Ligation-induced display of pId:MHCII on B cells could be of
importance in immune regulation. Thus, whenever Ag ligates the
BCR of a B cell, that B cell is anticipated to display both
pAg:MHCII and pId:MHCII complexes and thus be regulated by
both Ag-specific and Id-specific T cells. Such a mechanism would
effectively merge conventional (42, 46) and Id-driven (7, 13) T–B
collaboration.
The observation that DNP- and TNP-conjugated OVA were
somewhat less potent at inducing B cell responses than was anti-Id
Fig. 6. B cell responses to a BCR-specific T-independent type-2 antigen is enhanced by Id-specific T cells. (A) Experimental setup (n = 5 Id-sp. T/DNP-FICOLL;
n = 5 Id-sp. T/NIP-FICOLL; n = 3 DNP-FICOLL). Spleens were analyzed by IHC (B and C) or by FACS (D and E). (B) Representative cryosection from a recipient mouse
spleen immunostained using anti-λ BCR L chain Alexa Fluor 488 (green), peanut agglutinin Alexa Fluor 594 (red), and rat anti-mouse reticular fiber Ab (ER-TR7,
blue). (C) GCs quantified from immunostained spleen sections. (D) Germinal center B cells. GL7+ cells with λ L chains were gated among IgD− B cells (SI Appendix,
Fig. S17). (E) Plasma cells (CD138+) among splenocytes. (F) Serum concentrations of anti-Id Ig-reactive IgM, IgG, and DNP-reactive IgG on day 10. (G) CD40L
blockade by repetitive injection of anti-CD40L mAb or isotype-matched control. Effects on serum levels of Id+ IgM (day 5) and IgG1 (day 7). A detailed description
and analysis is given in SI Appendix, Fig. S18. Statistical comparisons: Tukey’s multiple comparisons tests (C–E), Dunn’s multiple comparisons test (F and G). *P ≤
0.05, **P ≤ 0.01, and ***P ≤ 0.005.



























































IgG may be related to the slightly lower affinity of the haptens for
the Id+ BCR. Further, filtration of TNP/DNP-OVA in the kidney,
and a binding of TNP/DNP to BCRs having irrelevant (non-Id) λ
chains, could also contribute. DNP-FICOLL was highly efficient,
but this may relate to the TI-2 nature of FICOLL. It should be
noted that DNP-FICOLL elicited much more potent responses
in the presence of Id-specific T cells, even when employing
LPS-stimulated B cells.
It has been hypothesized that Id-driven T–B collaboration
could cause development of autoimmune diseases, since autoreactive
B cells that have their BCR ligated by autoantigen could receive
help from Id-specific T helper cells (13, 25). Such Id-driven T–B
collaboration could easily become chronic, since self-antigens are
not readily eliminated, in contrast to exogenous antigens. The
persistent nature of Id-driven T–B collaboration could cause
development of autoimmune diseases and, after acquisition of
oncogenetic events, B cell lymphomas. Supporting the hypothesis,
chronic Id-driven T–B collaboration has been shown to elicit SLE-
like disease in mice (16, 25), with hallmarks of human SLE (15).
Moreover, Id-driven T–B collaboration has been associated with
multiple sclerosis in humans (19–21). Finally, chronic Id-driven
T–B collaboration initiated development of B cell lymphomas
in mice (17) and possibly CLL in humans (22). The influence of
BCR ligation could not be addressed in these studies. Here, in
support of the hypothesis, we demonstrate that BCR ligation is
required for efficient Id-driven T–B cell collaboration. This
suggests that (i) chronic ligation of the BCR by autoantigen
and (ii) persistent help from Id-specific T cells may synergize in
causing chronic proliferation of B cells and the development of
disease. This scenario is consistent with the observations that
not only autoimmune diseases (47) but also B cell cancers (48–51)
are associated with self-reactive BCRs. It should be stressed that
the hypothesis relates to the induction of B cell disorders. In later
phases of the disease, the requirement for BCR ligation and for Id-
specific T cell help could diminish as the pathologic B cells attain
an increasingly autonomous state.
Autoimmune diseases and B cell malignancies are relatively
rare disorders. Therefore, in most individuals, Id-driven T–B col-
laboration does not escalate beyond control but is down-regulated
over time. Such down-modulation might occur through a number
of suppressive mechanisms, such as peripheral exhaustion of Id-
specific T cells (52), deletion of Id-specific thymocytes (12), and
perhaps through the action of Id-specific T suppressor cells (53).
We here demonstrate the induction of Foxp3+ Id-specific regula-
tory T cells in the wake of Id-driven T–B collaboration; such cells
could contribute to down-regulation of the response. Presumably,
only when one or more of these suppressive mechanisms fail may
unchecked Id-driven T–B collaboration result in development of
autoimmunity and B cell cancers.
Experimental Outline. Extended materials and methods have been
added at the end of the SI Appendix after SI Appendix, Table S1
(p. 37–41). SI Appendix describes the generation of VDJH
315
mice (SI Appendix, Fig. S2, p. 5) and Vλ2315m mice (SI Appendix,
Fig. S3, p.7). Pages 7 and 8 describe the Id315 and λ2315 TG ×
VDJH
315 mice. Page 7 describes FACS characterization of splenic
and bone marrow B cell lineages. SI Appendix, Fig. S6 (p. 13)
shows generation of the anti-pId315:I-Ed scFv. SI Appendix, Fig.
S10 (p. 17) shows preparation and validation of the anti-Id F(ab)2.
SI Appendix, Figs.S13 and S14 show GL7 immunostaining (p. 21)
and immunofluorescence (p. 23) procedures. SI Appendix, Fig. S15
(p. 26) shows germinal center B cell sorting and sequencing pro-
cedures. Cell enrichment, in vitro stimulation cultures, and in vivo
transfer experiments are described in SI Appendix, Extended Ma-
terials and Methods (p. 37–38). ELISAs for Id+ IgM and IgG are
described in SI Appendix, Extended Materials and Methods (p. 38–39).
All antibodies for flow cytometry are described in SI Appendix,
Extended Materials and Methods (p. 39). λ Amplicon sequencing in
naïve Vλ2315 mice is described in SI Appendix, Extended Materials
and Methods (p. 39). Analyses of in vitro B cell responses, in-
cluding of Ca2+ flux measurements, and phosphotyrosine Western
blotting are described in SI Appendix, Extended Materials and
Methods (p. 40).
Data and Materials Availability. The V-gene modified mice and the
TCRm reagent may be obtained on a collaborative basis. Sequenc-
ing raw data from λ amplicon sequencing from the Vλ2315m+/−
mouse are available at the Sequence Read Archive. Identifiers
are BioSample SAMN10220898; sample name, VL2-315 B+/−;
SRA, SRS3891429; BioProject, PRJNA495162.
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